Biotech News
Related news
INABIN8bio2026-07-09 12:00 EST
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
NRIXNurix Therapeutics2026-08-04 11:00 EST
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
RVMDRevolution Medicines2026-06-23 12:00 EST
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
FATEFate Therapeutics2026-08-14 11:00 EST
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
MGNXMacroGenics2026-07-23 20:01 EST
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
RVMDRevolution Medicines2026-07-02 12:00 EST
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ARGXArgenx2026-08-17 05:00 EST
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
LEGNLegend Biotech Corporation2026-06-15 12:00 EST
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
LYELLyell Immunopharma2026-06-08 10:00 EST
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
IN8bio
Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...
Recent company news
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INABIN8bio2026-07-09 12:00 EST
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
INABIN8bio2026-06-03 12:30 EST
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
INABIN8bio2026-06-01 12:30 EST
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Stock data
- Close
- 1.28 USD
- Market cap
- 14.96M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States